# A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

> **NCT06855771** · PHASE2 · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 130 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** BMS-986504

## Key facts

- **NCT ID:** NCT06855771
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-09
- **Primary completion:** 2028-12-29
- **Final completion:** 2031-12-30
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06855771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06855771, "A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06855771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*